Related Experiment Videos
[Vasodilator agents and the vascular endothelium]
1Département de Pharmacologie, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre.
Annales De Cardiologie Et D'Angeiologie
|December 30, 1989
Summary
The discovery of endothelium-derived relaxation factor (EDRF) reclassifies vasodilators. EDRF-releasing drugs are endothelium-dependent, while others are independent, impacting cardiovascular disease treatment.
Area of Science:
- Cardiovascular Pharmacology
- Endothelial Biology
Context:
- The traditional classification of vasodilators for angina and heart failure is evolving.
- Endothelium-derived relaxation factor (EDRF) plays a crucial role in vascular function.
Purpose:
- To re-evaluate vasodilator classification based on EDRF release.
- To highlight the significance of the vascular endothelium in drug action.
Summary:
- Vasodilators are now classified as endothelium-dependent (inducing EDRF release) or independent.
- Nitric oxide is identified as the primary EDRF in synthetic vasodilators like sodium nitroprusside and SIN-1.
- Calcium-channel blockers and mediators like acetylcholine are endothelium-dependent.
- Flow-dependent vasodilation and pathological conditions (atherosclerosis, hypertension) influence endothelial modulation, potentially leading to contracting factor release.
Impact:
- This reclassification refines our understanding of vasodilator mechanisms.
- It underscores the critical role of the vascular endothelium in cardiovascular pharmacology.
- Recognizing endothelial modulation is vital for optimizing vasodilator therapy in various pathologies.